GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » INVO Bioscience Inc (NAS:INVO) » Definitions » Equity-to-Asset

INVO Bioscience (INVO Bioscience) Equity-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is INVO Bioscience Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. INVO Bioscience's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $0.01 Mil. INVO Bioscience's Total Assets for the quarter that ended in Mar. 2024 was $18.32 Mil. Therefore, INVO Bioscience's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.00.

The historical rank and industry rank for INVO Bioscience's Equity-to-Asset or its related term are showing as below:

During the past 13 years, the highest Equity to Asset Ratio of INVO Bioscience was 0.70. The lowest was -40.36. And the median was -1.56.

INVO's Equity-to-Asset is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.64
* Ranked among companies with meaningful Equity-to-Asset only.

INVO Bioscience Equity-to-Asset Historical Data

The historical data trend for INVO Bioscience's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INVO Bioscience Equity-to-Asset Chart

INVO Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.07 0.53 0.70 -0.24 0.04

INVO Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.26 0.02 0.04 -

Competitive Comparison of INVO Bioscience's Equity-to-Asset

For the Medical Devices subindustry, INVO Bioscience's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INVO Bioscience's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, INVO Bioscience's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where INVO Bioscience's Equity-to-Asset falls into.



INVO Bioscience Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

INVO Bioscience's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=0.893/20.888
=0.04

INVO Bioscience's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=0.01/18.318
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


INVO Bioscience  (NAS:INVO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


INVO Bioscience Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of INVO Bioscience's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


INVO Bioscience (INVO Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
5582 Broadcast Court, Sarasota, FL, USA, 34240
INVO Bioscience Inc operates as a medical device company focused on the Assisted Reproductive Technology (ART) marketplace that is creating simplified, lower-cost treatments for patients diagnosed with infertility. The company has developed the INVOcell device and procedure, the first Intravaginal Culture (IVC) system granted FDA clearance in the United States used for the incubation of eggs and sperm during fertilization and early embryo development. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors.
Executives
Trent D Davis director 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot director 802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum director 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren officer: Chief Financial Officer 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell director 61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina director 5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal director INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody director, officer: Medical Director 1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes officer: Acting CFO and PFO 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux 10 percent owner 8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff director, officer: CEO/Chairman 109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr officer: Chief Financial Officer 92 GOULD STREET, WAKEFIELD MA 01880